SG11202007200YA - Epilepsy treatment agent - Google Patents

Epilepsy treatment agent

Info

Publication number
SG11202007200YA
SG11202007200YA SG11202007200YA SG11202007200YA SG11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA SG 11202007200Y A SG11202007200Y A SG 11202007200YA
Authority
SG
Singapore
Prior art keywords
treatment agent
epilepsy treatment
epilepsy
agent
treatment
Prior art date
Application number
SG11202007200YA
Other languages
English (en)
Inventor
Hiroyuki Higashiyama
Hisashi Wakita
Yoshimasa Ito
Yoshihide Osada
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of SG11202007200YA publication Critical patent/SG11202007200YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202007200YA 2018-03-20 2019-03-18 Epilepsy treatment agent SG11202007200YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018052974 2018-03-20
PCT/JP2019/011184 WO2019181854A1 (fr) 2018-03-20 2019-03-18 Agent de traitement de l'épilepsie

Publications (1)

Publication Number Publication Date
SG11202007200YA true SG11202007200YA (en) 2020-08-28

Family

ID=67986497

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007200YA SG11202007200YA (en) 2018-03-20 2019-03-18 Epilepsy treatment agent

Country Status (13)

Country Link
US (1) US11660275B2 (fr)
EP (1) EP3769759B1 (fr)
JP (1) JP7265526B2 (fr)
KR (1) KR20200132858A (fr)
CN (1) CN111801096B (fr)
AU (1) AU2019239394A1 (fr)
BR (1) BR112020017835A2 (fr)
CA (1) CA3092295A1 (fr)
IL (1) IL276966A (fr)
MX (1) MX2020009100A (fr)
RU (1) RU2020128731A (fr)
SG (1) SG11202007200YA (fr)
WO (1) WO2019181854A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024026905A (ja) * 2020-11-25 2024-02-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 てんかん治療剤
WO2023210617A1 (fr) * 2022-04-27 2023-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 Composition pharmaceutique pour le traitement de la maladie de parkinson

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3383414A (en) 1964-08-26 1968-05-14 Sandoz Ag Benzocycloalkyl sulfamides
US3709677A (en) 1969-06-25 1973-01-09 Sandoz Ag N-substituted sulfamoyl compounds useful as herbicides
DE3623944A1 (de) 1986-07-16 1988-02-11 Thomae Gmbh Dr K Neue benzolsulfonamido-indanylverbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP1401805A1 (fr) 2001-06-26 2004-03-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives de valproyltaurinamide utilises comme anticonvulsants et agents cns actifs
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
MX2007002309A (es) 2004-08-24 2007-10-08 Johnson & Johnson Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos.
US20070155823A1 (en) 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
CN100572365C (zh) 2006-01-26 2009-12-23 全哲山 用作抗癫痫药的1,2,4-三唑并[4,3-a]喹啉-1-酮衍生物及其可药用盐
TW200812574A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
EP2026790A2 (fr) 2006-05-19 2009-02-25 Janssen Pharmaceutica, N.V. Thérapie combinée pour le traitement de l'épilepsie et de troubles apparentés
AR070949A1 (es) 2007-10-19 2010-05-19 Solvay Pharm Gmbh Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
CA2758105A1 (fr) 2009-04-09 2010-10-14 N.V. Organon Derives d'indane
ES2858337T3 (es) 2009-11-13 2021-09-30 Receptos Llc Moduladores selectivos del receptor de fosfato de esfingosina 1 y métodos de síntesis quiral
NZ599914A (en) 2009-11-13 2014-08-29 Receptos Inc Selective heterocyclic sphingosine 1 phosphate receptor modulators
US20120302546A1 (en) 2010-02-04 2012-11-29 Fox Chase Chemical Diversity Center, Inc. Novel sulfamides exhibiting neuroprotective action and methods for use thereof
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
WO2012137982A2 (fr) * 2011-04-05 2012-10-11 Takeda Pharmaceutical Company Limited Dérivé de sulfonamide et son utilisation
MY169073A (en) * 2012-06-21 2019-02-13 Eisai R&D Man Co Ltd Indanesulfamide derivative
AU2014367781B2 (en) 2013-12-19 2019-07-04 Eisai R&D Management Co., Ltd. Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain
KR102283895B1 (ko) * 2013-12-23 2021-07-30 노파르티스 아게 제약 조합물
CA3002930A1 (fr) 2015-11-13 2017-05-18 Eisai R&D Management Co., Ltd. Compose de pyranodipyridine

Also Published As

Publication number Publication date
RU2020128731A3 (fr) 2022-04-20
US11660275B2 (en) 2023-05-30
BR112020017835A2 (pt) 2020-12-29
KR20200132858A (ko) 2020-11-25
IL276966A (en) 2020-10-29
CN111801096B (zh) 2024-03-05
JPWO2019181854A1 (ja) 2021-03-11
EP3769759A1 (fr) 2021-01-27
WO2019181854A1 (fr) 2019-09-26
CN111801096A (zh) 2020-10-20
EP3769759B1 (fr) 2023-11-15
US20210000771A1 (en) 2021-01-07
EP3769759A4 (fr) 2021-11-17
JP7265526B2 (ja) 2023-04-26
CA3092295A1 (fr) 2019-09-26
MX2020009100A (es) 2020-12-03
RU2020128731A (ru) 2022-04-20
AU2019239394A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
IL269371A (en) Treatment methods
GB201813876D0 (en) Treatment
HK1252996A1 (zh) 用於治療癲癇的方法
HK1255224A1 (zh) 用於傷口的治療劑
HUE056213T2 (hu) Kezelõ berendezés
IL288937A (en) Improved treatment using eyp001
GB201800546D0 (en) Treatment
GB201913756D0 (en) Contrast agent
IL276966A (en) Epilepsy treatment factor
IL281839A (en) Treatment methods
IL281792A (en) Treatment methods
GB201713760D0 (en) Treatment of epilepsy
GB201914296D0 (en) Treatment
SI3307267T1 (sl) Zdravljenje multiple skleroze
SG11202101196TA (en) Behavioural treatment
GB201912760D0 (en) Treatment
GB201912365D0 (en) Treatment
GB201912335D0 (en) Treatment
GB201911816D0 (en) Treatment
GB201911603D0 (en) Treatment
GB201910755D0 (en) Treatment
GB201814905D0 (en) Treatment
GB201904253D0 (en) Treatment
GB201902579D0 (en) Treatment
GB201902580D0 (en) Treatment